Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.74 |
| ▸ | DRD2 | P14416 | 4/20 | 0.74 |
| ▸ | HTR2A | P28223 | 4/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | DRD4 | P21917 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | HTR2C | P28335 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | CCKBR | P32239 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | HRH1 | P35367 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30620874 | 0.93 | HTR1A (0.74) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL1566323 | 0.93 | HTR1A (0.74) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL1566550 | 0.93 | HTR1A (0.74) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL140810 | 0.93 | HTR1A (0.74) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL6025000 | 0.91 | HTR1A (0.69) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL16027132 | 0.91 | HTR1A (0.71) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL10006696 | 0.91 | HTR1A (0.76) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| Hydrochloric Acid SCHEMBL1545222 | 0.90 | HTR1A (0.68) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL8825541 | 0.90 | HTR1A (0.69) | HTR1ADRD2HTR2AHRH3ABCB11 | |
| SCHEMBL27462376 | 0.90 | HTR1A (0.76) | HTR1ADRD2HTR2AHRH3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002757-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180002759-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180002758-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180002756-A1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | VANDA PHARMACEUTICALS INC. | 2018-01-04 | — | — | US | disclosed |
| US-20150368718-A1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | VANDA PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9157121-B2 | Method of treatment based on polymorphisms of the KCNQ1 gene | VANDA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150225793-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225795-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225794-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-9074255-B2 | Method of predicting a predisposition to QT prolongation | VANDA PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130012542-A1 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-8293765-B2 | Injectable depot formulation comprising crystals of iloperidone | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8227488-B2 | Injectable depot formulation comprising crystals of iloperidone | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-20120059035-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058201-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120035215-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120027871-A1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | VANDA PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110212141-A1 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE | VANDA PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20100226858-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | VANDA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20090099232-A1 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE | WIECKHUSEN DIERK | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058201-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | TNNI3, FAM83A, FAM162A | HTR1A 825/4885DRD2 4578/4885HTR2A 2665/4885 |
| US-20150225793-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | TNNI3, FAM83A, FAM162A | HTR1A 825/4885DRD2 4578/4885HTR2A 2665/4885 |
| US-20110212141-A1 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE | IL36G, RPP30, IL2 | HTR1A 1921/4885DRD2 1998/4885HTR2A 2040/4885 |
| US-20130012542-A1 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE | IL36G, RPP30, IL2 | HTR1A 1921/4885DRD2 1998/4885HTR2A 2040/4885 |
| US-20120035215-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | SLC47A2, ABCC2, SLC47A1 | HTR1A 1408/4885DRD2 3297/4885HTR2A 1004/4885 |
| US-20090099232-A1 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE | IL36G, RPP30, IL2 | HTR1A 1921/4885DRD2 1998/4885HTR2A 2040/4885 |
| US-20180002757-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | TNNI3, FAM83A, FAM162A | HTR1A 825/4885DRD2 4578/4885HTR2A 2665/4885 |
| US-20180002758-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | TNNI3, TSG101, UGT1A3 | HTR1A 1021/4885DRD2 3065/4885HTR2A 1488/4885 |
| US-20180002756-A1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | KCNQ1, KCNN3, KCNQ2 | HTR1A 1377/4885DRD2 3536/4885HTR2A 1107/4885 |
| US-20180002759-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | SLC47A2, ABCC2, SLC47A1 | HTR1A 1408/4885DRD2 3297/4885HTR2A 1004/4885 |
| US-20120059035-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | TNNI3, TSG101, UGT1A3 | HTR1A 1021/4885DRD2 3065/4885HTR2A 1488/4885 |
| US-20150225795-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | TNNI3, TSG101, UGT1A3 | HTR1A 1021/4885DRD2 3065/4885HTR2A 1488/4885 |
| US-20150225794-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | SLC47A2, ABCC2, SLC47A1 | HTR1A 1408/4885DRD2 3297/4885HTR2A 1004/4885 |
| US-20150368718-A1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | KCNQ1, KCNN3, KCNQ2 | HTR1A 1377/4885DRD2 3536/4885HTR2A 1107/4885 |
| US-20100226858-A1 | METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION | CERS2, CERT1, SPTLC1 | HTR1A 4129/4885DRD2 4539/4885HTR2A 4386/4885 |
| US-20120027871-A1 | METHOD OF TREATMENT BASED ON POLYMORPHISMS OF THE KCNQ1 GENE | KCNQ1, KCNN3, KCNQ2 | HTR1A 1377/4885DRD2 3536/4885HTR2A 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.